Patent ID: 6943181

Claim:
A method of treating a migraine comprising administering to a patient a pharmaceutically effective amount of a pharmaceutical composition comprising at least one substituted γ-lactone compound of the formula I, in which R 1 denotes an optionally at least mono-substituted 2-pyridyl, 2-pyrimidyl, 3-pyrazolyl, 2-quinolinyl or 2-pyrazinyl residue, which may also be fused with a saturated or at least partially unsaturated hydrocarbon ring system, R 2 denotes an optionally at least mono-substituted, saturated, branched or unbranched aliphatic C 1-10 residue or an optionally at least mono-substituted, at least partially unsaturated, branched or unbranched aliphatic C 2-10 residue, R 3 denotes an optionally at least mono-substituted aryl residue, R 4 denotes H, or R 3 and R 4 together denote an optionally at least mono-substituted, saturated or at least mono-unsaturated aliphatic C 3-7 residue, with the proviso that the residue R 2 in this case denotes an optionally at least mono-substituted aryl residue, an optionally at least mono-substituted, saturated, branched or unbranched aliphatic C 1-10 residue or an optionally at least mono-substituted, at least partially unsaturated, branched or unbranched aliphatic C 2-10 residue, said compound being in the form of a racemate, a diastereomer or enantiomer as a free base or of a corresponding physiologically acceptable salt thereof.